Cooperation agreements between companies save on costs of health are not uncommon. Read additional details here: john k castle. Even in the health care industry, discount agreements are piling up between health insurers and pharmaceutical companies. As the private krankenversicherung.de insurance Portal reported, such agreements have downsides, however. First of all, such range contracts offer great savings with drug manufacturers for health insurance. Customers of such insurance this get an active ingredient the same preparation of the range of the contractual partner at reduced prices.
But these costs do not in any case be propagated to the insured. This is handled differently depending on the health insurance. The AXA private health insurance recently announced such cooperation with the Sandoz group Germany regarding the assortments of Sandoz and Hexal 1A Pharma. Customers benefit directly from this agreement. However, the international health insurance is the benefits from a similar Cooperation fully to their insured next. According to information of the Federal Association of Drugmakers, inserting same active ingredient preparations but can reduce the chances of treatment success.
They affect the cooperative behavior of patients in treatment, the so-called compliance. This was the result of a study of the market research company IMS health, which examined a corresponding prescription change in lipid lowering, antidepressants and insulins. In comparison to the previous treatment, a change of the impact occurred after switching to generic, although same active ingredient, drugs also who were even medically detectable by means of blood sugar and cholesterol measurements. More information: news.private-krankenversicherung.de/…/ Rebate contracts… Contact: Lisa Neumann University first media GmbH barefoot streets 12 04109 Leipzig Tel: + 49/341/49288-240 fax: + 49/341/49288-59